Masanao Kurata
Research Subjects
Masanao Kurata has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Goro Honda
Department of Surgery, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital
10 shared publicationsKoji Tsuruta
4 shared publications- Sohei Satoi
Department of Pancreatobiliary Surgery, Kansai Medical University, Hirakata, Japan
4 shared publications - Terumi Kamisawa
Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan
4 shared publications A-Hon Kwon
3 shared publications- Fuyuhiko Motoi
Department of Surgery, Tohoku University Graduate School of Medicine
3 shared publications
Latest Publications
- Open Access
- 21 March 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-12
Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients
Carbohydrate antigen (CA) 19–9 levels after resection are considered to predict prognosis; however, the significance of decreased CA19–9 levels after neoadjuvant therapy has not been clarified. This study aimed to define the prognostic significance of decreased CA19–9 levels after neoadjuvant therapy in patients with pancreatic adenocarcinoma. Between 2001 and 2012, 240 consecutive patients received neoadjuvant therapy and subsequent resection at seven high-volume institutions in Japan. These patients were divided into three groups: Normal group (no elevation [≤37 U/ml] before and after neoadjuvant therapy), Responder group (elevated levels [> 37 U/ml] before neoadjuvant therapy but decreased levels [≤37 U/ml] afterwards), and Non-responder group (elevated levels [> 37 U/ml] after neoadjuvant therapy). Analyses of overall survival and recurrence patterns were performed. Uni- and multivariate analyses were performed to clarify the clinicopathological factors influencing overall survival. The initial metastasis sites were also evaluated in these groups. The Responder group received a better prognosis than the Non-responder group (3-year overall survival: 50.6 and 41.6%, respectively, P = 0.026), but the prognosis was comparable to the Normal group (3-year overall survival: 54.2%, P = 0.934). According to the analysis of the receiver operating characteristic curve, the CA19–9 cut-off level defined as no elevation after neoadjuvant therapy was ≤103 U/ml. The multivariate analysis revealed that a CA19–9 level ≤ 103 U/ml, (P = 0.010, hazard ratio: 1.711; 95% confidence interval: 1.133–2.639), tumor size ≤27 mm (P = 0.040, 1.517; (1.018–2.278)), a lack of lymph node metastasis (P = 0.002, 1.905; (1.276–2.875)), and R0 status (P = 0.045, 1.659; 1.012–2.627) were significant predictors of overall survival. Moreover, the Responder group showed a lower risk of hepatic recurrence (18%) compared to the Non-responder group (31%), though no significant difference in loco-regional, peritoneal or other distant recurrence were observed between groups (P = 0.058, P = 0.700 and P = 0.350, respectively). Decreased CA19–9 levels after neoadjuvant therapy predicts a better prognosis, with low incidence of hepatic recurrence after surgery.
- 21 March 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 1-12
Open AccessDecreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients
Carbohydrate antigen (CA) 19–9 levels after resection are considered to predict prognosis; however, the significance of decreased CA19–9 levels after neoadjuvant therapy has not been clarified. This study aimed to define the prognostic significance of decreased CA19–9 levels after neoadjuvant therapy in patients with pancreatic adenocarcinoma. Between 2001 and 2012, 240 consecutive patients received neoadjuvant therapy and subsequent resection at seven high-volume institutions in Japan. These patients were divided into three groups: Normal group (no elevation [≤37 U/ml] before and after neoadjuvant therapy), Responder group (elevated levels [> 37 U/ml] before neoadjuvant therapy but decreased levels [≤37 U/ml] afterwards), and Non-responder group (elevated levels [> 37 U/ml] after neoadjuvant therapy). Analyses of overall survival and recurrence patterns were performed. Uni- and multivariate analyses were performed to clarify the clinicopathological factors influencing overall survival. The initial metastasis sites were also evaluated in these groups. The Responder group received a better prognosis than the Non-responder group (3-year overall survival: 50.6 and 41.6%, respectively, P = 0.026), but the prognosis was comparable to the Normal group (3-year overall survival: 54.2%, P = 0.934). According to the analysis of the receiver operating characteristic curve, the CA19–9 cut-off level defined as no elevation after neoadjuvant therapy was ≤103 U/ml. The multivariate analysis revealed that a CA19–9 level ≤ 103 U/ml, (P = 0.010, hazard ratio: 1.711; 95% confidence interval: 1.133–2.639), tumor size ≤27 mm (P = 0.040, 1.517; (1.018–2.278)), a lack of lymph node metastasis (P = 0.002, 1.905; (1.276–2.875)), and R0 status (P = 0.045, 1.659; 1.012–2.627) were significant predictors of overall survival. Moreover, the Responder group showed a lower risk of hepatic recurrence (18%) compared to the Non-responder group (31%), though no significant difference in loco-regional, peritoneal or other distant recurrence were observed between groups (P = 0.058, P = 0.700 and P = 0.350, respectively). Decreased CA19–9 levels after neoadjuvant therapy predicts a better prognosis, with low incidence of hepatic recurrence after surgery.
- Open Access
- 1 January 2017
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 78 (10) , 2317-2323
A Solid Pseudopapillary Neoplasm of the Pancreas in a Male Patient
症例は38歳,男性で,検診の腹部超音波検査にて膵頭部に径4cm超の腫瘤を指摘された.CT・MRI・超音波内視鏡検査および穿刺吸引細胞診からsolid pseudopapillary neoplasm(以下,SPNと略記)と診断し,腹腔鏡下幽門輪温存膵頭十二指腸切除術を施行した.手術時間は8時間22分,出血量は155mlで,術後経過良好で18日目に退院した.病理組織学的に腫瘍は間質に微細な石灰化を散見し,類円形に腫大した濃染核を有する異型細胞が乳頭状構造や胞巣状構造を形成していた.免疫組織化学的にβ-cateninが核および細胞質において陽性,CD56陽性,synaptophysin陽性,chromogranin A一部陽性であり,SPNと診断した.術後22カ月経過して無再発生存中である.男性の膵SPNは比較的まれであるが近年報告例が増加し,その特徴は女性例とやや異なるといわれている.
- 1 January 2017
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 78 (10) , 2317-2323
Open AccessA Solid Pseudopapillary Neoplasm of the Pancreas in a Male Patient
症例は38歳,男性で,検診の腹部超音波検査にて膵頭部に径4cm超の腫瘤を指摘された.CT・MRI・超音波内視鏡検査および穿刺吸引細胞診からsolid pseudopapillary neoplasm(以下,SPNと略記)と診断し,腹腔鏡下幽門輪温存膵頭十二指腸切除術を施行した.手術時間は8時間22分,出血量は155mlで,術後経過良好で18日目に退院した.病理組織学的に腫瘍は間質に微細な石灰化を散見し,類円形に腫大した濃染核を有する異型細胞が乳頭状構造や胞巣状構造を形成していた.免疫組織化学的にβ-cateninが核および細胞質において陽性,CD56陽性,synaptophysin陽性,chromogranin A一部陽性であり,SPNと診断した.術後22カ月経過して無再発生存中である.男性の膵SPNは比較的まれであるが近年報告例が増加し,その特徴は女性例とやや異なるといわれている.
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S319
Sa1451 Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S319
Sa1451 Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis
- 1 June 2015
- Vol. 62 (140) , 1031-6
A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.
To determine the recommended dose (RD) for full-dose S-1 and low-dose gemcitabine combined with radiotherapy in patients with non-metastatic advanced pancreatic cancer. Adult patients with non-metastatic advanced pancreatic cancer (Union for International Cancer Control T stage 3 or 4) were eligible. The weekly intravenous gemcitabine (level 0-1: 200 mg/ml,level 2: 300 mg/m on Days 1, 8, 15, 22, 29, 36) dose was escalated starting from level 1 in a 3+3 design along with full dose twice-daily oral S-1 (level 0: 60 mg/m2/day, level 1-2: 80 mg/ml/day), and was administered on the same days as radiotherapy (1.8 Gy x 28 days). Eight patients were included in this study. A dose-limiting toxicity (DLT) (grade 4 neutropenia) was observed in one of the first three patients in level 1, and three additional patients received the level 1 dose without any severe adverse events. DLTs (grade 3/4 neutropenia) were then observed in the first two patients given level 2 dose. Therefore, level 1 was designated as the RD. Common grade 3/4 toxicities included neutropenia (62.5%), anorexia (37.5%), and pneumonitis (12.5%). The combination of S-1 and gemcitabine with concurrent radiotherapy is a feasible regimen at the level 1 dose.
- 1 June 2015
- Vol. 62 (140) , 1031-6
A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.
To determine the recommended dose (RD) for full-dose S-1 and low-dose gemcitabine combined with radiotherapy in patients with non-metastatic advanced pancreatic cancer. Adult patients with non-metastatic advanced pancreatic cancer (Union for International Cancer Control T stage 3 or 4) were eligible. The weekly intravenous gemcitabine (level 0-1: 200 mg/ml,level 2: 300 mg/m on Days 1, 8, 15, 22, 29, 36) dose was escalated starting from level 1 in a 3+3 design along with full dose twice-daily oral S-1 (level 0: 60 mg/m2/day, level 1-2: 80 mg/ml/day), and was administered on the same days as radiotherapy (1.8 Gy x 28 days). Eight patients were included in this study. A dose-limiting toxicity (DLT) (grade 4 neutropenia) was observed in one of the first three patients in level 1, and three additional patients received the level 1 dose without any severe adverse events. DLTs (grade 3/4 neutropenia) were then observed in the first two patients given level 2 dose. Therefore, level 1 was designated as the RD. Common grade 3/4 toxicities included neutropenia (62.5%), anorexia (37.5%), and pneumonitis (12.5%). The combination of S-1 and gemcitabine with concurrent radiotherapy is a feasible regimen at the level 1 dose.
- 20 January 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (3_suppl) , 426
The oncologic impact of pancreatic fistula after pancreatectomy in patients with pancreatic cancer.
426 Background: There is a few reports that evaluates the association between pancreatic and long-term survival after pancreatectomy in patients with pancreatic cancer. The aim of this study was to elucidate the oncological impact of pancreatic fistula (PF) on long-term survival after pancreatectomy in patients with pancreatic cancer by performing a survey of high volume centers for pancreatic resection in Japan. Methods: Between January 2001 and December 2012, 1,369 patients who underwent pancreatectomy for pancreatic cancer at 7 high-volume centers in Japan were retrospectively reviewed. Results: Pancreatic fistula(PF) occurred in 320 of 1,369 patients (23.5%), and these were classified based ISGPF as follows; grade A in 10.2%, grade B in 10.7%, and grade C in 2.6% of the patients. Median survival time (MST) in no fistula/grade A, grade B and grade C were 24.0, 26.3 and 11.0 months, respectively. MST in grade B PF was similar with that in no fistula/grade A. However, patients with grade C PF had a significantly poorer survival than those without (P
- 20 January 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (3_suppl) , 426
The oncologic impact of pancreatic fistula after pancreatectomy in patients with pancreatic cancer.
426 Background: There is a few reports that evaluates the association between pancreatic and long-term survival after pancreatectomy in patients with pancreatic cancer. The aim of this study was to elucidate the oncological impact of pancreatic fistula (PF) on long-term survival after pancreatectomy in patients with pancreatic cancer by performing a survey of high volume centers for pancreatic resection in Japan. Methods: Between January 2001 and December 2012, 1,369 patients who underwent pancreatectomy for pancreatic cancer at 7 high-volume centers in Japan were retrospectively reviewed. Results: Pancreatic fistula(PF) occurred in 320 of 1,369 patients (23.5%), and these were classified based ISGPF as follows; grade A in 10.2%, grade B in 10.7%, and grade C in 2.6% of the patients. Median survival time (MST) in no fistula/grade A, grade B and grade C were 24.0, 26.3 and 11.0 months, respectively. MST in grade B PF was similar with that in no fistula/grade A. However, patients with grade C PF had a significantly poorer survival than those without (P
- Open Access
- 1 January 2015
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 76 (5) , 1187-1191
Laparoscopic Enucleation of an Insulinoma of the Pancreatic Uncinate Process
- 1 January 2015
- Published by Japan Surgical Association in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
- Vol. 76 (5) , 1187-1191
Open AccessLaparoscopic Enucleation of an Insulinoma of the Pancreatic Uncinate Process
- 1 June 2014
- Published by Elsevier in Pancreatology
- Vol. 14 (3) , S90
Can surgical resection be acceptable in pancreatic cancer patients with positive peritoneal washing cytology?
- 1 June 2014
- Published by Elsevier in Pancreatology
- Vol. 14 (3) , S90
Can surgical resection be acceptable in pancreatic cancer patients with positive peritoneal washing cytology?
- Open Access
- 24 April 2013
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 216 (6) , e73-e76
Novel Device for Pancreaticojejunostomy via a Pure Laparoscopic Approach
Although minimally invasive surgery has rapidly evolved to include a variety of complex surgical procedures, laparoscopic pancreaticoduodenectomy (PD) has yet to be accepted as a generalized surgical method for the resection of pancreatic head lesions. The main reasons are both the difficulty and time consumption of pancreaticoenteric anastomosis,1 x 1 Kim, S.C., Song, K.B., Jung, Y.S. et al. Short-term clinical outcomes for 100 consecutive cases of laparoscopic pylorus-preserving pancreatoduodenectomy: improvement with surgical experience. Surg Endosc. 2013; 27: 95–103 Crossref | PubMed | Scopus (92) | Google Scholar See all References , 2 x 2 Keck, T., Küsters, S., Wellner, U.F. et al. Total laparoscopic partial pancreatoduodenectomy and reconstruction via laparoscopic pancreatogastrostomy. Langenbecks Arch Surg. 2012; 397: 1009–1012 Crossref | PubMed | Scopus (9) | Google Scholar See all References and involve not only the challenge of accurate needle handling, but also tangling of a number of sutures that have been retained without ligation after stitching. Therefore, we used a modified Kakita method,3 x 3 Kakita, A., Yoshida, M., and Takahashi, T. History of pancreaticojejunostomy in pancreaticoduodenectomy: development of a more reliable anastomosis technique. J Hepatobiliary Pancreat Surg. 2001; 8: 230–237 Crossref | PubMed | Scopus (87) | Google Scholar See all References which is familiar to most Japanese pancreatic surgeons as a simple and safe method for open pancreaticojejunostomy (P-JS), and we created a novel device, Haenawa (Fig. 1 Fig. 1 ), for this method. We herein describe our experiences of PD and middle pancreatectomy (MP). As background, in Japanese, Haenawa means a fishing trawl line consisting of a number of fishhooks.
- 24 April 2013
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 216 (6) , e73-e76
Open AccessNovel Device for Pancreaticojejunostomy via a Pure Laparoscopic Approach
Although minimally invasive surgery has rapidly evolved to include a variety of complex surgical procedures, laparoscopic pancreaticoduodenectomy (PD) has yet to be accepted as a generalized surgical method for the resection of pancreatic head lesions. The main reasons are both the difficulty and time consumption of pancreaticoenteric anastomosis,1 x 1 Kim, S.C., Song, K.B., Jung, Y.S. et al. Short-term clinical outcomes for 100 consecutive cases of laparoscopic pylorus-preserving pancreatoduodenectomy: improvement with surgical experience. Surg Endosc. 2013; 27: 95–103 Crossref | PubMed | Scopus (92) | Google Scholar See all References , 2 x 2 Keck, T., Küsters, S., Wellner, U.F. et al. Total laparoscopic partial pancreatoduodenectomy and reconstruction via laparoscopic pancreatogastrostomy. Langenbecks Arch Surg. 2012; 397: 1009–1012 Crossref | PubMed | Scopus (9) | Google Scholar See all References and involve not only the challenge of accurate needle handling, but also tangling of a number of sutures that have been retained without ligation after stitching. Therefore, we used a modified Kakita method,3 x 3 Kakita, A., Yoshida, M., and Takahashi, T. History of pancreaticojejunostomy in pancreaticoduodenectomy: development of a more reliable anastomosis technique. J Hepatobiliary Pancreat Surg. 2001; 8: 230–237 Crossref | PubMed | Scopus (87) | Google Scholar See all References which is familiar to most Japanese pancreatic surgeons as a simple and safe method for open pancreaticojejunostomy (P-JS), and we created a novel device, Haenawa (Fig. 1 Fig. 1 ), for this method. We herein describe our experiences of PD and middle pancreatectomy (MP). As background, in Japanese, Haenawa means a fishing trawl line consisting of a number of fishhooks.
- Open Access
- 23 November 2011
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 9 (1) , 153
Main-duct intraductal papillary mucinous adenoma of the pancreas
Background: The prevalence of carcinoma in main-duct intraductal papillary mucinous neoplasm (IPMN) is high, and surgical resection is recommended for all patients with a main-duct IPMN. Results: A main-duct IPMN with typical imagings including protruding lesions in the dilated main pancreatic duct was resected, but the histology was intraductal papillary mucinous adenoma of the pancreas. Discussion: It has been reported that the presence of mural nodules and dilatation of MPD are significantly higher in malignant IPMNs. The presented case had protruding lesions in the dilated main pancreatic duct on endoscopic ultrasonography, but the histology was adenoma. Conclusion: Preoperative distinction between benign and malignant IPMNs is difficult.
- 23 November 2011
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 9 (1) , 153
Open AccessMain-duct intraductal papillary mucinous adenoma of the pancreas
Background: The prevalence of carcinoma in main-duct intraductal papillary mucinous neoplasm (IPMN) is high, and surgical resection is recommended for all patients with a main-duct IPMN. Results: A main-duct IPMN with typical imagings including protruding lesions in the dilated main pancreatic duct was resected, but the histology was intraductal papillary mucinous adenoma of the pancreas. Discussion: It has been reported that the presence of mural nodules and dilatation of MPD are significantly higher in malignant IPMNs. The presented case had protruding lesions in the dilated main pancreatic duct on endoscopic ultrasonography, but the histology was adenoma. Conclusion: Preoperative distinction between benign and malignant IPMNs is difficult.
- 12 August 2010
- Vol. 57, 447-50
FDG-PET/CT findings of autoimmune pancreatitis.
This study aimed to evaluate the clinical utility in Fluorine-18 fluorodeoxyglucose-positron emission tomography (FDG-PET)/ computed tomography (CT) in the management of patients with autoimmune pancreatitis (AIP), with special emphasis on differentiating AIP from pancreatic cancer (PC). FDG-PET/CT findings of 10 AIP patients were compared with those of 14 PC patients. There were no significant differences between AIP and PC in early and delayed maximum standardized uptake value (SUV(max)), and in the ratio of delayed to early SUV(max). Abnormal extrapancreatic FDG uptake was observed in 5 AIP patients, in the hilar lymph nodes (n = 4), mediastinal lymph nodes (n = 2), abdominal lymph nodes (n = 2), and bilateral salivary glands (n = 2). After steroid therapy, the abnormal FDG uptake in the pancreas disappeared almost completely in two patients, and the FDG uptake in the hilar, mediastinal and abdominal lymph nodes decreased in one patient. FDG-PET/CT may be helpful to differentiate AIP from PC by assessing FDG-uptake patterns in the pancreas and extrapancreatic lesions, it may have the potential to assess the disease activity of AIP and its extrapancreatic lesions, and it may be useful as a monitoring marker for tapering or stopping steroid therapy.
- 12 August 2010
- Vol. 57, 447-50
FDG-PET/CT findings of autoimmune pancreatitis.
This study aimed to evaluate the clinical utility in Fluorine-18 fluorodeoxyglucose-positron emission tomography (FDG-PET)/ computed tomography (CT) in the management of patients with autoimmune pancreatitis (AIP), with special emphasis on differentiating AIP from pancreatic cancer (PC). FDG-PET/CT findings of 10 AIP patients were compared with those of 14 PC patients. There were no significant differences between AIP and PC in early and delayed maximum standardized uptake value (SUV(max)), and in the ratio of delayed to early SUV(max). Abnormal extrapancreatic FDG uptake was observed in 5 AIP patients, in the hilar lymph nodes (n = 4), mediastinal lymph nodes (n = 2), abdominal lymph nodes (n = 2), and bilateral salivary glands (n = 2). After steroid therapy, the abnormal FDG uptake in the pancreas disappeared almost completely in two patients, and the FDG uptake in the hilar, mediastinal and abdominal lymph nodes decreased in one patient. FDG-PET/CT may be helpful to differentiate AIP from PC by assessing FDG-uptake patterns in the pancreas and extrapancreatic lesions, it may have the potential to assess the disease activity of AIP and its extrapancreatic lesions, and it may be useful as a monitoring marker for tapering or stopping steroid therapy.